Page Banner

United States Department of Agriculture

Agricultural Research Service

You are here: ARS Home / Collaborating / Office of Technology Transfer / Animal Health
Animal Health
headline bar

Each year, approximately 60 new patents are issued by the U.S. Patent Office for USDA inventions. The Office of Technology Transfer (OTT) transfers these inventions through licenses to the private sector for commercialization. Below are links to the new technologies that are available for licensing. 

 

Docket

Title

Description

Contact

87.13  NEW

 

 

 

 

 

 

 

SPONTANEOUSLY IMMORTALIZED AVIAN CELL LINE

 

 

 

 

 

 

A spontaneously immortalized avian cell line, designated ZS-1, derived from the primary chicken embryonic fibroblasts

Potential Commercial Applications
-Production of viral agents, e.g., recombinant viral agents, expression of recombinant proteins, diagnostic assays of pathological specimens, etc.

Competitive Advantages
-The immortal cell line is free of avian leukosis virus (ALV) and yet susceptible to all subgroups of ALV, including subgroup E
-Supports virus replication

renee.wagner@ars.usda.gov

173.09  NEW

 

 

 

 

 

 

 

 

 

 

 

PHAGE TWORT ENDOLYSIN CHAP DOMAIN IS LYTIC FOR STAPHYLOCOCCUS AUREUS

 

 

 

 

 

 

 

 

 

 

A potential antimicrobial treatment to combat S. aureus mastitis. The invention is a nucleic acid sequence encoding an antimicrobial peptidoglycan hydrolase polypeptide, the Phage Twort (PlyTW) endolysin, a protein that attacks the cell wall peptidoglycan of S. aureus.  Both the full length phage Twort endolysin PlyTW and truncated PlyTW (PlyTW Δ172-373) lyse live S. aureus, including multidrug-resistant staphylococci.  Truncated PlyTW (PlyTW Δ172-373) lacks the amidase domain of the full length PlyTW, but has higher lytic activity.  
 
Potential Commercial Applications
-Treatment for mastitis as well as for infection and other human diseases caused by S. Aureus
-Potentially used to produce novel protein fusion antimicrobials believed to be refractory to antibiotic resistance development

Competitive Advantages
- Useful as an alternative antibiotic treatment to the multidrug-resistant S. aureus

james.poulos@ars.usda.gov

 

5.12   NEW

 

 

 

 

 

 

 

 

 

 

 

 

ANTIMICROBIAL ENZYME FUSIONS REDUCE RESISTANCE AND KILL INTRACELLULAR STAPHYLOCOCCUS AUREUS

 

 

 

 

 

 

 

 

 

Engineered triple-acting staphylolytic peptidoglycan hydrolases where three unique antimicrobial activities from two parental proteins are combined into a single fusion protein, effectively reducing the incidence of resistant strain development. The fusion protein reduced colonization by S. aureus in a rat nasal colonization model, surpassing the efficacy of either parental protein.

Potential Commercial Applications
-A new antimicrobial to combat S. aureus infection in animals and humans

Competitive Advantages
-Modification of the triple-acting lytic construct with a protein transduction domain significantly enhanced both biofilm eradication and the ability to kill intracellular Staphylococcus aureus as demonstrated in cultured cells, and mouse models of staphylococcal mastitis and osteomyelitis
-Alternative antibiotic treatment to the multidrug-resistant S. aureus

james.poulos@ars.usda.gov

186.11 + 79.14
NEW

 

 

 

 

 

 

 

HIGH AFFINITY MONOCLONAL ANTIBODIES FOR DETECTION OF SHIGA TOXIN 2 (STX2)

 

 

 

 

 

 

High affinity monoclonal antibodies against Shiga toxin strain Stx2 and hybridomas that produce such antibodies are described. The antibodies may be used in a kit for detecting Stx2 and variants thereof in a sample.

 

Potential Commercial Applications

- Basis for developing a sensitive immunoassays for detecting variants for Shiga toxin 2

- Immunoassys could be used for monitoring and source-tracking food supplies as well as monitoring contamination of clinical and environmental samples such as feces, soil, air, and water.

 

Competitive Advantages

- The hybridoma cell lines produce monoclonal antibodies that detect all four variants of Stx2

- Immunoassays are rapid, highly specific and sensitive

 david.nicholson@ars.usda.gov

 

 

2.14   NEW

 

 

METHOD FOR BED BUG CONTROL

A low oxygen treatment method for bed bug control. The method comprises placing a bed-bug contaminated object in a sealable enclosure and establishing reduced oxygen (<3%) conditions for an amount of time sufficient to control bed bugs.

Potential Commercial Applications

- An effective and safe treatment to bed bug problems

 

Competitive Advantages

-Environmental friendly method that does not rely on heat, pesticides or insecticides

- Unlikely to have any negative impact on treated objects

 david.nicholson@ars.usda.gov

 

 

35.14  NEW

 

 

INTRAVITREAL INJECTION OF A CHIMERIC PHAGE ENDOLYSIN PLY187; PROTECTION FROM STAPHYLOCOCCUS AUREUS ENDOPHTHALMITIS

A novel antimicrobial protein derived from a virus that infects bacteria has been tested and shown to reduce or eradicate staphylococcal bacteria infecting the eye ball in a mouse model of eye infection. The antimicrobial protein evaluated is Ply187AN-KSH3b, a chimeric phage endolysin derived from the Ply187 prophage. Intravitreal injection in C57BL/6 mouse eyes of chimeric Ply187AN-KSH3b (both at 6 and 12 h post infection) significantly improved the outcome of staphylococcal endophthalmitis, preserved retinal structural integrity, and maintained visual function. Phage lysin treatment significantly reduced the bacterial burden and the levels of inflammatory cytokines and neutrophil infiltration in the eyes.

 

Potential Commercial Applications

There is a need for antimicrobial treatments into the eyeball to cure staphylococcus infections of the eye, especially following cataract surgery.

 

Competitive Advantages

- Staphylococci are notoriously prone to antibiotic resistance development. This protein works on the outside of the pathogen, thereby avoiding many resistance mechanisms that conventional intracellular antibiotics lack.

- This protein works through the digestion of the peptidoglycans which result in the lysis of the bacterial cells. This mode of action is especially important due to the ‘immune privileged’ status of the eye, where unlike most other body cavities, immune cells do not invade.

james.poulos@ars.usda.gov

 

 

 

 

 

 

 

 


Last Modified: 5/5/2015
Footer Content Back to Top of Page